What Emery Pharma does

Emery Pharma is a Contract Research Organization (CRO) founded in 2011 and headquartered in Alameda, California, delivering customized analytical, bioanalytical, microbiological, and consulting services to pharmaceutical and biotechnology companies across the drug development lifecycle. The company operates a single-site laboratory at 1000 Atlantic Ave Suite #110, staffed by a small team of PhD-level scientists and analytical chemists, and maintains the regulatory credential stack required for regulated pharmaceutical work — FDA registration, DEA licensing for controlled substances, GLP and cGMP certification, and ISO/IEC 17025 compliance for extractables and leachables studies.

The laboratory's technical platform is anchored in mass spectrometry and chromatography: High Resolution Orbitrap and triple-quadrupole LC-MS/MS systems, 400 MHz NMR, UPLC with CAD/DAD/RI detectors, GC-MS/FID, and the Meso Scale Discovery electrochemiluminescence immunoassay platform, complemented by an extensive bacterial strain collection including ESKAPE pathogens and multidrug-resistant clinical isolates. Service lines span analytical method development and validation (ICH Q2(R2), USP <1224>), impurity analysis and profiling (nitrosamines, benzene, elemental impurities under ICH Q3D), pharmaceutical stability testing, extractables and leachables, biologics characterization (peptide mapping, intact mass, PTM, HCP, DAR for ADCs, biosimilar comparability), bioanalytical and DMPK/DDI services, formulation development, metabolomics, botanical drug development, and cell and microbiology services.

Emery Pharma generates revenue through project-based contracts with enterprise pharmaceutical and biotechnology clients, with pricing tailored to scope, complexity, and regulatory tier (GLP/cGMP vs. R&D) and billed under multi-year contract cadences. Go-to-market is sales-led via direct enterprise engagement and a "Request a Proposal" funnel, supported by content marketing through a scientific blog and resources library. The company also offers consulting and litigation support for patent, product liability, and regulatory matters. Customer segments are primarily traditional pharma and biotech, with a secondary segment of virtual biotechs and program teams lacking internal analytical infrastructure.

Name

Emery Pharma

Legal name

Emery Pharma

Website

https://emerypharma.com

Company type

Private

Founded year

2011

Operating status

Operating

Headcount range

1–10 employees

Short description

Emery Pharma is a private, FDA-registered and GLP/cGMP-certified Contract Research Organization in Alameda, California, providing analytical, bioanalytical, biologics characterization, microbiology, and impurity testing services to pharmaceutical and biotechnology clients across drug development.

Ownership category

akta.pro rank

Product category

Contract Research Organization (Pharmaceutical Analytical & Bioanalytical Laboratory Services)

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity) (HLAGAAAD)

akta.pro secondary industries

Toxicology & Safety Assessment CROs (GLP) (HLAGAAAC), Impurity / Reference Standard Synthesis & Characterization (HLAGAHAG), Quality Engineering & Risk Management (ICH Q9/Q10, validation, change control) (HLAGAKAL)

Keywords

• Contract research services
• Analytical laboratory testing
• Bioanalytical services
• Biologics characterization
• Impurity analysis profiling

Headquarters

HQ city

Alameda

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Contract Research Services: Emery Pharma generates revenue through providing customized contract research laboratory services to pharmaceutical and biotechnology clients. Services include analytical method development, bioanalytical services, stability testing, impurity analysis, biologics characterization, and cell/microbiology services. The revenue model is project-based with quotes tailored to client outsourcing needs.

Pricing tiers

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Core offering

Emery Pharma is a Contract Research Organization (CRO) providing GLP/cGMP-compliant laboratory services to pharmaceutical and biotechnology companies. Its core offerings include analytical chemistry and method development/validation, bioanalytical testing for PK/PD and DMPK, biologics characterization (including ADCs and biosimilars), impurity analysis (nitrosamines, benzene, elemental impurities), extractables and leachables studies, formulation development, stability testing, cell and microbiology services, botanical drug development, and consulting/expert-witness support. All engagements are project-based and customized to client outsourcing needs.

Product overview

Emery Pharma is a Contract Research Organization (CRO) delivering a comprehensive portfolio of laboratory services for pharmaceutical and biotechnology drug development. The company operates as a GLP/cGMP-compliant laboratory providing analytical services (including method development, validation, LC-MS, NMR, HPLC, GC-MS, high-resolution mass spectrometry, proteomics, and metabolomics), bioanalytical services (including DMPK, DDI bioanalysis, ELISA, MSD immunoassays, and qualitative bioanalysis), cell and microbiology services (including antibiotic resistance testing and antimicrobial synergy studies), impurity analysis and profiling services (including nitrosamine and benzene testing), extractables and leachables studies, formulation development, pharmaceutical stability testing, biologics characterization services, botanical drug development support, and consulting and litigation support. The company maintains state-of-the-art instrumentation including Orbitrap mass spectrometers, triple quad LC-MS/MS systems, HPLC/UPLC platforms, GC-MS, and NMR spectroscopy. These services support preclinical and clinical drug development from early-stage research through regulatory submissions.

Differentiator

Problem solved

Functional benefit

Products and services

• Analytical Services Full-service analytical chemistry laboratory supporting preclinical drug development including method development and validation, LC-MS services, NMR services, HPLC/UPLC, GC-MS, high-resolution mass spectrometry, proteomics, metabolomics, and reference standard synthesis for pharmaceutical and biotechnology sponsors.
• Biologics Characterization Services Comprehensive analytical support for proteins, antibodies, and complex biologics including peptide mapping, intact mass analysis, post-translational modification analysis, host-cell protein analysis, comparability studies, and drug-antibody ratio analysis for ADC characterization for biopharmaceutical sponsors.
• Extractables and Leachables (E&L) Studies Controlled extraction studies and leachables stability testing for pharmaceutical and medical device products following ISO/IEC 17025 guidelines, including Soxhlet, reflux, and sonication extraction techniques and analytical techniques such as LC-MS, GC-MS, ICP-MS, and NMR.
• Pharmaceutical Release Testing Services cGMP-compliant release testing and compendial assay services including compendial methods testing (USP/NF, EP/JP) and custom validated release assay development for APIs, biologics, peptides, and oligonucleotides per ICH Q2(R2) guidelines.
• Impurity Analysis and Profiling Services Detection, quantitation, and characterization of organic and inorganic impurities including degradation products, residual solvents, process-related impurities, and elemental contaminants following ICH Q3, ICH M7, ICH Q3D, and USP <232>/<233> guidelines for pharmaceutical and biotechnology sponsors.
• Pharmaceutical Stability Testing Services Comprehensive stability testing services under ICH Q1A(R2), Q1B, Q1C, Q1D, Q1E, and Q5C guidelines including custom R&D stability studies and ICH-compliant long-term, intermediate, and accelerated studies across all climate zones for pharmaceutical and biotechnology sponsors.
• Analytical Method Development, Transfer & Validation Services GLP/GMP-compliant method development, validation, and transfer services for small molecules, biologics, oligonucleotides, and peptides using LC-MS/MS, UPLC, NMR, HRMS, GC-MS, and LBA platforms following ICH Q2(R2) and USP <1224> guidelines for pharmaceutical and biotechnology sponsors.
• Benzene Impurity Analysis Specialized analytical testing for detection and quantitation of benzene impurities in drug substances and products using Headspace Gas Chromatography with Mass Spectrometry (HS-GC/MS) supporting compound-specific risk assessment and regulatory compliance for pharmaceutical clients.
• Formulation Development Services Drug formulation development services including pre-formulation studies, formulation trials, functional assays (dissolution testing, IVRT/IVPT), stability assessments, and scalability support from prototype through commercial batches for pharmaceutical sponsors.
• Metabolomics Services Comprehensive metabolomics analysis including targeted metabolomics, untargeted metabolomics, lipidomics, and metabolomic flux analysis using UPLC-HRMS, UPLC-QqQ-MS/MS, GC-MS, and NMR platforms for pharmaceutical and biotechnology clients.
• Bioanalytical Services Mass spectrometry-based bioanalysis supporting pharmacokinetics, pharmacodynamics, and drug metabolism studies with LC-MS/MS, HRMS, and GC-MS platforms following ICH M10 guidelines for GLP and non-GLP sample analysis for pharmaceutical and biotechnology sponsors.
• DMPK and Drug-Drug Interaction Bioanalytical Services DMPK and DDI bioanalytical services including PK bioanalysis, immunogenicity and anti-drug antibody testing, CYP enzyme induction/inhibition studies, metabolite analysis, and in vitro ADME assays (Caco-2, PAMPA, hepatocyte stability, microsomal stability) for pharmaceutical and biotechnology sponsors.
• ELISA and MSD Immunoassays Immunoassay services for large molecule quantitation including custom ELISA development and validation, MSD (Meso Scale Discovery) multiplex assay development, pharmacokinetics and pharmacodynamics biomarker analysis, and immunogenicity testing (ADA, nAb) for biopharmaceutical sponsors.
• Ligand Binding Assays Ligand binding assay services including ELISA development, binding kinetics analysis, and regulatory-compliant assay validation for drug development and clinical diagnostics applications for pharmaceutical and biotechnology sponsors.
• Qualitative Bioanalysis Services Metabolite identification and characterization (MetID) and untargeted metabolomics analysis using NMR, LC-HRMS, GC-MS, and LC-MS/MS platforms for drug metabolism studies and biomarker discovery for pharmaceutical and biotechnology sponsors.
• Botanical Drug Development Services Specialized services for botanical drug discovery and development including analytical chemistry, biochemistry, formulation science, natural products characterization, and regulatory submissions support from IND through clinical trials for botanical and natural product pharmaceutical sponsors.
• Cell & Microbiology Services Microbiological characterization services including antibiotic resistance testing with multidrug-resistant clinical isolates and ESKAPE pathogens, antimicrobial synergy studies, biofilm eradication testing, cytotoxicity testing, MIC determination, and time-kill kinetics assays for pharmaceutical and biotechnology clients.
• Nitrosamine Testing Services Specialized nitrosamine impurity analysis services for pharmaceutical products including method development and validation under cGMP conditions for detection and quantitation of N-nitrosamine compounds for pharmaceutical clients responding to regulatory nitrosamine concerns.
• Consulting & Litigation Support Services Expert analytical analysis and litigation support services provided by leading scientists in drug development for pharmaceutical legal disputes including patent litigation, product liability cases, and regulatory investigations for legal teams, sponsors, and regulatory bodies.

Quantifiable outcome

• Projects delivered on time
• +2 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature10 records

Partnerships

One partnership is on record.

• RaynerminorStrategic or Co-development PartnerEmery Pharma and Rayner announced a successful publication validating a bioanalytical method for quantifying ketorolac in human vitreous and aqueous humor using a surrogate matrix of human plasma, in accordance with ICH M10 guidelines. This collaboration demonstrates joint scientific expertise in ophthalmic bioanalysis.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Eurofins Scientific: Global testing giant with extensive pharmaceutical services including bioanalytical, stability, impurity analysis, E&L and GMP release testing — broad incumbent that competes with Emery Pharma across nearly every service line at larger scale.
• Pharmaron: Integrated CRO offering bioanalytical, CMC, biologics and impurity testing services — overlapping with Emery Pharma in regulated small-molecule and biologics analytical testing.
• Charles River Laboratories: Large preclinical and bioanalytical CRO offering regulated bioanalysis, biologics characterization, microbiology and GMP testing services — competes for the same enterprise client programs from a much broader portfolio.
• WuXi AppTec / WuXi STA: Global CRO/CDMO providing bioanalytical, CMC, biologics characterization and impurity testing — overlapping with Emery Pharma's analytical and bioanalytical work, though at much larger scale.
• IQVIA Laboratories: Global CRO offering bioanalytical, biomarker, central lab and GMP-compliant testing services — broad incumbent competing for the same regulated assay work.
• PPD (Thermo Fisher Scientific): Global CRO with extensive bioanalytical, GMP lab and biologics characterization services — competes with Emery Pharma for enterprise biopharma analytical and bioanalytical work.

Direct peers

• Bioanalytical Systems (BASi): Specialty CRO providing bioanalytical, DMPK, and drug metabolism services including in vitro ADME and LC-MS/MS quantification — overlapping with Emery Pharma's DMPK/DDI and bioanalytical services.
• MicroConstants: Specialty bioanalytical CRO focused on LC-MS/MS PK, immunogenicity and biomarker assays — closest mid-sized U.S. peer to Emery Pharma's bioanalytical services.
• KCAS Bioanalytical & Biomarker Services: Specialty bioanalytical CRO focused on LC-MS/MS, immunogenicity (ADA/nAb), biomarker and PK analysis — closely comparable to Emery Pharma's bioanalytical, ELISA/MSD and DMPK offerings.
• Frontage Laboratories: U.S.-headquartered bioanalytical and CMC CRO offering LC-MS/MS, HRMS, biologics characterization and method development — directly overlapping Emery Pharma's bioanalytical and analytical service portfolio for small molecules and biologics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance13 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Emery Pharma